Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 627 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Rhinosinusitis
Interventions
oral levofloxacin, nebulized levofloxacin
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Rochester, New York
Conditions
Bipolar Disorder
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
53
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more
Conditions
Otorrhea, Otitis Media With Effusion in Children
Interventions
Otiprio, Ciprodex
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
6 Months to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Stenotrophomonas Infection
Interventions
Levofloxacin, trimethoprim-sulfamethoxazole
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
1,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Acute Otitis Externa
Interventions
Ciprodex®, EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension
Drug
Lead sponsor
Exela Pharma Sciences, LLC.
Industry
Eligibility
6 Months and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
46
States / cities
Birmingham, Alabama • Mesa, Arizona • Jonesboro, Arkansas + 36 more
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions
Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York + 1 more
Conditions
Huntington's Disease
Interventions
PF-02545920, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 65 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
Conditions
Phenylketonuria
Interventions
sapropterin dihydrochloride, Moxifloxacin, Moxifloxacin placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more
Conditions
UTI - Lower Urinary Tract Infection, Antibiotic Resistant Infection
Interventions
Ciprofloxacin
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cary, North Carolina
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo, Moxifloxacin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Healthy Subjects
Interventions
1.25 mg/kg BL-8040 + BL-8040-matching placebo, 2 mg/kg BL-8040, BL-8040-matching placebo, 400 mg Moxifloxacin (1x400 mg tablet)
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Bipolar Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
20
States / cities
Little Rock, Arkansas • Riverside, California • Deerfield Beach, Florida + 17 more
Conditions
Major Depressive Disorder
Interventions
Antidepressant + Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
58
States / cities
Mesa, Arizona • Peoria, Arizona • Beverly Hills, California + 55 more
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Wallingford, Connecticut
Conditions
Healthy Volunteers
Interventions
BGB-3111, Placebo, Moxifloxacin
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia

NCT00209027
Conditions
Schizophrenia
Interventions
fMRI, Aripiprazole
Other · Drug
Lead sponsor
Emory University
Other
Eligibility
20 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Fragile X Syndrome
Interventions
Aripiprazole
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Terminated Phase 4 Interventional Results available

Antipsychotic Effects on Brain Function in Schizophrenia

NCT01913327
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Aripiprazole, Risperidone, Modafinil
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Conditions
Community Acquired Bacterial Pneumonia
Interventions
Delafloxacin, Moxifloxacin, Linezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Montgomery, Alabama • Newark, Delaware • Coral Gables, Florida + 21 more
Conditions
Urinary Tract Infection
Interventions
Cipro XR (Ciprofloxacin, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 33 more
Conditions
Schizophrenia
Interventions
Aripiprazole (Abilify®) IM Depot Injection
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
119
States / cities
Dothan, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 97 more
Conditions
Eating Disorders
Interventions
Olanzapine, Aripiprazole
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
16 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
New York, New York